Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Anika Therapeutics held its Annual Meeting on June 20, 2025, with 86.13% shareholder participation (12.35M shares represented). Key outcomes include:
- Board Elections: Three Class II directors elected until 2028 - Cheryl Blanchard, Joseph Capper, and Glenn Larsen, with Capper receiving strongest support (10.5M votes)
- 2017 Omnibus Incentive Plan Amendment: Shareholders approved increasing reserved shares by 475,000 to total 5.76M shares. All shares may be granted as incentive stock options under IRC Section 422
- Other Approvals: Shareholders ratified Deloitte & Touche as independent auditor (12.07M votes in favor) and approved executive compensation in advisory vote (8.37M votes in favor)
The meeting demonstrated strong shareholder engagement, though some proposals like executive compensation and incentive plan amendment faced notable opposition with over 2.5M votes against each.